BLISSGVSNSEBliss GVS Pharma Limited· PharmaceuticalsMediumNeutral
Announced Fri, 3 Apr · 18:42 IST

Bliss GVS Pharma Limited has informed the Exchange regarding Appointment of Mr Deepak Rameshchandra Shah as Non- Executive Independent Director of the company w.e.f. April 03, 2026.

Management Changes View source PDF

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.9%1-day move
₹234.80
prior close
₹235.09
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.9-2.1-2.1-0.4+0.9+8.0+8.2+10.3+11.2+10.6+15.8+14.1+79.5+108.7
Up moveDown movePending
AI summary

Bliss GVS Pharma has appointed two new Non-Executive Independent Directors, Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah, with effect from April 3, 2026, for a 5-year term ending April 2, 2031. The appointments were approved via a circular resolution by the Board, based on the recommendation of the Nomination and Remuneration Committee. Mr. Mahadevan is a Chartered Accountant with over 35 years of finance leadership experience across Alcon, Sandoz, Novartis, and SHV Energy. Mr. Shah is a Fellow Chartered Accountant with 36+ years of experience in taxation and audit, and currently serves on the boards of Ruby Mills, Marathon Nextgen Realty, and Siyaram Silk Mills. The appointments are subject to shareholder approval via postal ballot.

Likely market impact

Strengthens the board with experienced independent directors, potentially improving governance and financial oversight. No immediate material impact on stock price expected, though long-term governance quality may improve.